u regulator rule pain drug u food drug regulator decide friday whether recommend sale painkiller link high risk heart attack stroke food drug administration fda advisory panel give verdict hearing evidence three day painkiller call inhibitor sell brand name celebrex vioxx vioxx withdrawn shop last year merck say would consider sell get fda approval fda ask decide benefit patient justify increased risk put vioxx back shelve likely boost profit merck make easy legal battle people claim injure drug analyst say merck voluntarily stop sale vioxx september move cause firm earnings slide year earlier merck share tumble news company set aside million dollar cover cost litigation alarm bell rung research note call approve show risk heart attack stroke double patient take drug least month inhibitor develop drug company include merck pfizer cause user few stomach problem painkiller pfizer still sell celebrex bextra product though investigation suggest may also harmful heart merck announcement possible reintroduction vioxx catch analyst surprise merck head research peter kim say withdrew vioxx base information available u time know alternative therapy go say thing since change light new report give new information clear cardiovascular risk observe approve make vioxx unique class similar drug market u mr kim explain thursday david graham fda office drug safety tell advisory panel really appear need inhibitor accord calculation present u senate dr graham november vioxx may link many american death face stem criticism handle vioxx case fda say tuesday create independent body oversee safety drug already market place european regulator meanwhile rule thursday patient heart disease stroke take inhibitor european medicine agency also say doctor cautious give drug patient risk factor heart disease